California's state prescription drug label sells one product: a long-acting insulin glargine pen, five per pack, at a suggested retail price of no more than $55. Seven months after launch, that remains the entire insulin lineup.
Vials are not available. Rapid-acting insulin is not available. And the $50 million California had set aside to build its own in-state manufacturing facility was eliminated from the budget, meaning the state is currently a brand on someone else's product rather than a manufacturer.
None of that makes the program a failure. The pens are real, the price is real and lower than the market, and pharmacists can substitute them for Lantus without a new prescription. But the gap between what CalRx is today and what was announced matters for patients trying to determine whether it applies to them.
Pens Only, and the Vial Users Are Still Waiting
The product currently sold is CalRx Insulin Glargine, available to pharmacies at $45 and to consumers at a suggested maximum of $55 for a five-pack of 3 mL pens, roughly $11 per pen. The state compares that with the $89 to $411 it says most popular brand names charge before retail markups or consumer discounts.
It is designated as interchangeable with Lantus, which is the operative fact for patients. Interchangeable means a pharmacist can substitute it for an existing insulin prescription without a new order from a prescriber. The state's patient materials note that the product is available in pen form only and that vials will follow at a later date.
The pen-only limitation excludes a meaningful group. Patients who use insulin vials with syringes, often because vials are cheaper per unit under their coverage or because they use a pump, cannot access CalRx. The biosimilar insulin page does not give a date.
There is also no CalRx short-acting insulin. Most people with type 1 diabetes and many with type 2 use a basal insulin alongside a mealtime insulin, so a household on a basal-bolus regimen can currently source only half of it through the state label. California has said it is working with Civica Rx to bring rapid-acting insulin aspart to market under the CalRx brand, with no announced date.
The single-pen question comes up constantly, and the answer is no. The product is sold only as a five-pack at a maximum price of $55. The $11 figure is an average, not a purchasable unit.
A White Label Product Is Not the Same as State Manufacturing
The most common misconception about CalRx is that California manufactures insulin. It does not.
The current product is a white-label arrangement: Civica Rx, a nonprofit manufacturer, secured an agreement with Biocon Biologics, and the resulting FDA-approved insulin is sold under the CalRx brand and pricing. The state set the price and put its name and a grizzly bear on the box. Final filling and packaging happen at a Civica facility in Petersburg, Virginia, according to a state fact sheet.
The original plan went further. California allocated $100 million to the effort, including $50 million to develop insulin products under a 10-year agreement with Civica and $50 million to build an in-state manufacturing facility. The facility funding was eliminated in the fiscal year 2025-26 budget as a savings measure. Civica separately continues developing its own biosimilar insulin glargine to be sold under the CalRx label, which would replace the current white-label product with something closer to the original concept.
The distinction affects durability rather than today's price. A state that sets a price on someone else's product depends on that arrangement continuing. A state that manufactures controls supply.
Seven months in, California has distributed more than 120,000 five-pen packs, though the state does not track how many were actually dispensed to patients, a gap MedicalDaily reported this week. Reporting by KFF Health News found pharmacists stocking the product without having dispensed any, and one who did not know it existed. Health policy researchers quoted in that reporting described the effort as valuable but limited in scope, covering a small number of drugs.
Naloxone Set the Template, and Albuterol Is Next
CalRx did not begin with insulin, and the program's structure is better understood by looking at what came before.
Established by executive order in 2019 and signed into law as the California Affordable Drug Manufacturing Act of 2020, the program targets drugs for which a generic or biosimilar exists but whose market prices remain high. Its first product was naloxone, the opioid overdose reversal medication, offered at a fraction of prevailing retail prices.
The next announced initiative is a School Albuterol Access Initiative, listed as coming soon on the program's main page. Stocking albuterol in schools addresses a specific gap: a child having an asthma attack whose own inhaler is at home or expired.
That sequence describes the actual model. CalRx is not attempting to replace the pharmaceutical market. It picks individual products with a large price gap and a clear clinical case, then uses purchasing and branding to set a public price without rebates or coupons, as the state announcement emphasized.
For patients deciding whether it applies to them, the calculation is specific. The people who benefit most are uninsured Californians, people between coverage, patients early in a high-deductible plan year before the deductible is met, and anyone needing an emergency supply. Insured patients may already pay less, since California caps insulin cost-sharing at $35 for a monthly supply under state law, and the state has reached agreements with several health plans to cover CalRx insulin on their formularies.
Anyone interested should ask the pharmacist for CalRx by name and request that both the cash and insured prices be run. Not every pharmacy stocks it, though many can order it. The product is available at Amazon, Costco, and at some CVS, Walgreens, and Walmart locations. No one should switch insulin products or change a dose without telling their prescriber, since any change warrants monitoring, even when the products are interchangeable.
No timeline has been announced for vials, for insulin aspart, or for the Civica-manufactured CalRx glargine. MedicalDaily will report new products and availability changes.
Key Questions Answered
What insulin does CalRx actually sell? One product: insulin glargine in pen form, sold as a five-pack of 3 mL pens at a suggested maximum retail price of $55. It is interchangeable with Lantus.
Are vials available? No. The state says vials will come at a later date and has not announced one. Patients who use vials with syringes cannot currently access CalRx.
Is there a fast-acting CalRx insulin? No. California says it is working to bring rapid-acting insulin aspart to market under the label, with no announced timeline.
Does California manufacture this insulin? No. The current product is a white-label arrangement through Civica Rx with Biocon Biologics, with final filling and packaging done in Virginia. The $50 million allocated for an in-state facility was eliminated in the 2025-26 budget.
Can someone buy a single pen for $11? No. It is sold only as a five-pack at a maximum of $55. The $11 figure is an average per pen.
Is a new prescription needed to switch? No. The product is designated as interchangeable, so a pharmacist can substitute it using an existing insulin prescription. Switching should still be discussed with a clinician.
Who benefits most from the price? Uninsured residents, people between coverage, patients early in a high-deductible plan year, and anyone needing an emergency supply. Insured patients may already pay less under California's $35 monthly insulin cap.
